Abstract
Clostridioides difficile is a major causative pathogen for antibiotic-associated diarrhea and C. difficile infections (CDIs) may lead to life-threatening diseases in clinical settings. Most of the risk factors for the incidence of CDIs, i.e., antibiotic use, treatment by proton pump inhibitors, old age, and hospitalization, are associated with dysbiosis of gut microbiota and associated metabolites and, consequently, treatment options for CDIs include normalizing the composition of the intestinal microbiome. In this review, with an introduction to the CDI and its global epidemiology, CDI-associated traits of the gut microbiome and its metabolites were reviewed, and microbiome-targeting treatment options were introduced, which was approved recently as a new drug by the United States Food and Drug Administration (U.S. FDA), rather than a medical practice.
| Original language | English |
|---|---|
| Article number | 995 |
| Journal | Antibiotics |
| Volume | 13 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Clostridioides diffcile
- Clostridioides diffcile infections
- gut microbiota dysbiosis
- microbiota-based therapeutics
Fingerprint
Dive into the research topics of 'Gut Microbiota and New Microbiome-Targeted Drugs for Clostridioides difficile Infections'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver